Scallon BJ - Search Results

1

Functional, Biophysical, and Structural Characterization of Human IgG1 and IgG4 Fc Variants with Ablated Immune Functionality.

Tam SH, McCarthy SG, Armstrong AA, Somani S, Wu SJ, Liu X, Gervais A, Ernst R, Saro D, Decker R, Luo J, Gilliland GL, Chiu ML, Scallon BJ. Tam SH, et al. Among authors: scallon bj. Antibodies (Basel). 2017 Sep 1;6(3):12. doi: 10.3390/antib6030012. Antibodies (Basel). 2017. PMID: 31548527 Free PMC article.

2

Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities.

Tam SH, McCarthy SG, Brosnan K, Goldberg KM, Scallon BJ. Tam SH, et al. Among authors: scallon bj. MAbs. 2013 May-Jun;5(3):397-405. doi: 10.4161/mabs.23836. Epub 2013 Apr 2. MAbs. 2013. PMID: 23549129 Free PMC article.

3

An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.

Vafa O, Gilliland GL, Brezski RJ, Strake B, Wilkinson T, Lacy ER, Scallon B, Teplyakov A, Malia TJ, Strohl WR. Vafa O, et al. Methods. 2014 Jan 1;65(1):114-26. doi: 10.1016/j.ymeth.2013.06.035. Epub 2013 Jul 17. Methods. 2014. PMID: 23872058

4

Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.

Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS. Scallon BJ, et al. Mol Immunol. 2007 Mar;44(7):1524-34. doi: 10.1016/j.molimm.2006.09.005. Epub 2006 Oct 11. Mol Immunol. 2007. PMID: 17045339

5

Engineering host cell lines to reduce terminal sialylation of secreted antibodies.

Naso MF, Tam SH, Scallon BJ, Raju TS. Naso MF, et al. Among authors: scallon bj. MAbs. 2010 Sep-Oct;2(5):519-27. doi: 10.4161/mabs.2.5.13078. Epub 2010 Sep 1. MAbs. 2010. PMID: 20716959 Free PMC article.

6

Quantitative in vivo comparisons of the Fc gamma receptor-dependent agonist activities of different fucosylation variants of an immunoglobulin G antibody.

Scallon B, McCarthy S, Radewonuk J, Cai A, Naso M, Raju TS, Capocasale R. Scallon B, et al. Int Immunopharmacol. 2007 Jun;7(6):761-72. doi: 10.1016/j.intimp.2007.01.014. Epub 2007 Feb 15. Int Immunopharmacol. 2007. PMID: 17466910

7

Contribution of FcRn binding to intestinal uptake of IgG in suckling rat pups and human FcRn-transgenic mice.

Kliwinski C, Cooper PR, Perkinson R, Mabus JR, Tam SH, Wilkinson TM, Giles-Komar J, Scallon B, Powers GD, Hornby PJ. Kliwinski C, et al. Am J Physiol Gastrointest Liver Physiol. 2013 Feb 1;304(3):G262-70. doi: 10.1152/ajpgi.00340.2012. Epub 2012 Dec 6. Am J Physiol Gastrointest Liver Physiol. 2013. PMID: 23220220 Free article.

8

Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.

Shealy DJ, Cai A, Staquet K, Baker A, Lacy ER, Johns L, Vafa O, Gunn G 3rd, Tam S, Sague S, Wang D, Brigham-Burke M, Dalmonte P, Emmell E, Pikounis B, Bugelski PJ, Zhou H, Scallon BJ, Giles-Komar J. Shealy DJ, et al. Among authors: scallon bj. MAbs. 2010 Jul-Aug;2(4):428-39. doi: 10.4161/mabs.12304. Epub 2010 Jul 1. MAbs. 2010. PMID: 20519961 Free PMC article.

9

Chimeric antibodies with extended half-life in ferrets.

Nesspor TC, Scallon B. Nesspor TC, et al. Influenza Other Respir Viruses. 2014 Sep;8(5):596-604. doi: 10.1111/irv.12273. Epub 2014 Jul 30. Influenza Other Respir Viruses. 2014. PMID: 25074755 Free PMC article.

10

Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders.

Benson JM, Peritt D, Scallon BJ, Heavner GA, Shealy DJ, Giles-Komar JM, Mascelli MA. Benson JM, et al. Among authors: scallon bj. MAbs. 2011 Nov-Dec;3(6):535-45. doi: 10.4161/mabs.3.6.17815. Epub 2011 Nov 1. MAbs. 2011. PMID: 22123062 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

33 results

Search Page